Company
Sydney, OS
Every investor coverage indicates participated in a round Sunshine Heart, Inc raised.
Companies Sunshine Heart, Inc acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Sunshine Heart, Inc. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures' news page points to an attached document announcing Sunshine Heart's appointment of Warren Watson to its board; the page itself carries only the headline and date.
GBS Ventures reposts a 2013 notice that Sunshine Heart signed a $25 million financing agreement with Aspire Capital Fund, with details only in an attached download.
Brief November 2012 notice reporting that Sunshine Heart won unconditional American regulator clearance to run a pivotal United States trial of its C-Pulse heart device, with detail left to an attached document.
A bare stub on GBS Ventures' site dated December 2011, pointing readers to a downloadable ASX announcement about Sunshine Hearts; the page itself gives no details of the announcement's contents.
A stub news post on GBS Ventures' site flagging that Sunshine Heart's feasibility trial findings were due for presentation at a cardiology conference, with an attached document available for download.
A brief 2011 post from GBS Ventures linking to an attached ASX announcement about early results from Sunshine Heart's C-Pulse feasibility trial, released by Ohio State.
A brief 2011 notice recording that Sunshine Heart brought in A$7.4 million through a two-part private placement, with the ASX filing attached for download.
Profile of Sunshine Heart's C-Pulse heart pump, its US trials and trial funding plans, recalling the failure of fellow Australian device maker Ventracor during the global financial crisis.
A short GBS Ventures news post from May 2011 pointing readers to an attached CEO update document about Sunshine Heart; the page itself gives no details.
A brief GBS Ventures notice pointing readers to an attached document about the stock exchange's query to Sunshine Heart over a recent movement in its share price.
Sunshine Heart's chief executive reports to shareholders on the C-Pulse trial: halfway through its US feasibility study, first two minimally invasive implants completed and new hospitals in Australia, Canada and the US joining.
A reposted ASX announcement from Sunshine Heart reports the first minimally invasive implant of its C-Pulse heart assist system, carried out in early June by a Louisville surgeon under a US FDA feasibility trial.
Sunshine Heart has completed a $1.75 million share placement and announced a rights issue, with about $4.65 million pledged so far, including cornerstone commitments from CM Capital and GBS Venture Partners.
Medical device maker Sunshine Heart reports its first two American C-Pulse patients cleared three-month follow-ups, booked initial reimbursement revenue from an Ohio trial site, and outlines coming CE Mark and FDA steps.
Sunshine Heart reports the first two US implants of its C-Pulse heart assist device, performed at Ohio State under a 20-patient FDA-approved feasibility trial running across six American hospitals.
A 2009 GBS Ventures news stub whose only content is a download link to a document about Sunshine Heart's first implants of its Pulse device; the page itself states no deal, amount or people.
Sunshine Heart says the US FDA approved a reimbursement category for its C-Pulse heart assist trial, opening Medicare reimbursement; it retained Quorum Consulting and expects patient enrollment at six US institutions in late 2008.
US regulators have conditionally cleared Sunshine Heart to begin its first American trial of the C-Pulse heart assist device in moderate heart failure patients, with enrollment at six institutions.
Sunshine Heart says the US regulator has conditionally cleared its first American trial of the C-Pulse heart assist device, with about twenty patients to enrol across six US hospitals from late 2008.
Sunshine Heart announced Dr Richard Lin will step down from its board at the November 2007 AGM, with Three Arch Partners nominating Dr Conrad Wang to stand for election in his place.
Sunshine Heart's Sydney subsidiary has named Victor Windeyer general manager while he remains chief operating officer of the American-listed parent, overseeing Australian operations ahead of a planned United States clinical trial filing.
Medical device company Sunshine Heart has contracted US research organisation Alquest to manage its North American clinical trial of the C-Pulse heart assist device.
Sunshine Heart, an ASX-listed medical device company, appoints Brian Bolton as its chief financial officer and company secretary from April 2007, thanking interim CFO Steven Skinner, ahead of United States clinical trials.
Two American heart failure specialists have agreed to serve as co-principal investigators for Sunshine Heart's C-Pulse feasibility trial, which the company says adds credibility as it prepares a wider US study in 2007.
Device maker Sunshine Heart said its C-Pulse product moved closer to human trials in America after a positive regulator meeting, with a formal application planned for mid-2007 and hospitals already lined up.
Heart device company Sunshine Heart added cardiologists Marc Silver and David Kaye to its medical advisory board in mid-2006, expanding a panel that guides work on its C-Pulse heart failure treatment.
Sunshine Heart says co-founder Crispin Marsh will swap his executive corporate affairs role for a non-executive board seat from mid-2006, as the medical device maker brings in senior staff including a new COO.
A stub news page from GBS Ventures linking to an attached ASX release concerning Sunshine Heart, dated December 2005; the document's contents are not reproduced on the page.
GBS Ventures' news page carries a brief entry linking to a downloadable Sunshine Heart ASX announcement, without describing what the announcement contains.
A stub page on GBS Ventures' site offering a downloadable Sunshine Heart investor update from October 2005; the page itself carries no content, figures, or transactions.
Sunshine Heart reported that surgeons at Auckland City Hospital implanted its C-Pulse heart device in a Class III heart failure patient, the procedure opening a trial of up to ten patients.